Publications

Our Science Library

Evidence-based Support for the Human-to-Pet Pipeline

Our process is rather simple. Beginning with FDA-approved medicines that have been extensively studied in human patients, we ensure that existing published data demonstrates that the human clinical experience carries over to dogs and cats.

Lastly, our pet-specific products are clinically and meaningfully improved by our team of experts.

Human Originator

Extensively studied in human patients, we start with well characterized FDA approved medicines.

Suboptimal

Published data demonstrate that the human clinical experience carries over to dogs and cats.

Pet-specific

OKAVA’s pet-specific products are clinically and meaningfully improved

Products

Human Drugs in Humans

In this review paper, the inventor of mycophenolate mofetil (MMF) describes the drug’s mechanism of action.

Immunopharmacology. 2000; 47(2-3):85-118.

With a long history in human medicine, the clinical utility of mycophenolic acid for treating inflammatory skin disease (psoriasis) was initially published in the 1970’s

The Journal of Investigative Dermatology. 1975; 65:537-542.

As demonstrated in this clinical study, MMF has been used to treat human patients with moderate-to-severe atopic dermatitis that have a poor response to conventional treatment with steroids and cyclosporine.

Archives in Dermatology 2001. 137(7):870-873.

The increasing use of MMF in the treatment of patients with various autoimmune inflammatory diseases is reviewed in this paper.

Clinical Pharmacokinetic. 2013. 52(5):303-31.

Human Drugs in Pets

The OKAVA teams reviews the emerging use of MMF to treat canine patients across a host immune-mediated disease.

Journal of Veterinary Pharmacology and Therapeutics. 2019; 42(2):127-138.

MMF is commonly used to treat human lupus patients. In these two papers, the successful use of MMF to treat a dogs with lupus is presented.

Veterinary Dermatology 2019; 30(4):350-e102 Veterinary Science 2021; 8(5):72

Recent consensus guidelines from ACVIM recommend MMF as an adjunctive agent for the treatment of immune-mediated hemolytic anemia.

Journal of Veterinary Internal Medicine 2019; 33(3):1141-1172

Although highly effective in canine patients, this OKAVA publication highlights the challenges of using the immediate release [human] formulation in dogs.

Journal of Veterinary Pharmacology and Therapeutics. 2021.

Pet-Specific Medicines

The Proof-of-Concept paper for OKV-1001 demonstrates that the modified release formulation is meaningfully differentiated over the originator [human] MMF immediate release formulation.

Frontiers in Veterinary Science. 2021.

This clinical trial replicates well-established studies in people and demonstrates that OKV 1001 is safe and effective in treating household dogs with chronic itch (or atopic dermatitis) who responded poorly to conventional treatment options.

Veterinary Dermatology 2024

Human Drugs in Humans

A detailed overview of the multifaceted nature of glucagon-like peptide-1 (GLP-1), an important incretin hormone, and its therapeutic role in various diseases is reviewed in this paper.

Molecular Metabolism. 2019; 30:72-130.

The evolution and advancements of GLP-1 receptor agonists (GLP-1RAs), viewed through the lens of randomized clinical studies, have established GLP-1RAs as a cornerstone treatment for diabetes.

Diabetes Obesity and Metabolism 2018; 20(Suppl 1):22-33

Landmark studies demonstrating that GLP-1RAs are safe and effective weight-loss agents.

Diabetes Care. 2010;33(6):1255-61 New England Journal of Medicine 2021. 384:989-1002

The clinical importance of adherence and persistence, as well as the associated challenges of achieving good compliance in real-world settings, are well documented.

Scientific Reports. 2018; 8:12190 Diabetes Care 2017; 40(11): 1469-1478

Human Drugs in Pets